Epigenetic targets in the diagnosis and treatment of prostate cancer.
Prostate cancer (PC) is one of leading cause of cancer related deaths in men. Various aspects of cancer epigenetics are rapidly evolving and the role of 2 major epigenetic changes including DNA methylation and histone modifications in prostate cancer is being studied widely. The epigenetic changes are early event in the cancer development and are reversible. Novel epigenetic markers are being studied, which have the potential as sensitive diagnostic and prognostic marker. Variety of drugs targeting epigenetic changes are being studied, which can be effective individually or in combination with other conventional drugs in PC treatment. In this review, we discuss epigenetic changes associated with PC and their potential diagnostic and therapeutic applications including future areas of research.
Manoharan
Murugesan
M
Department of Urology, Miller School of Medicine, University of Miami, Miami, Florida 33101, USA. mmanoharan@med.miami.edu
Ramachandran
Kavitha
K
Soloway
Mark S
MS
Singal
Rakesh
R
D014408:Biomarkers, Tumor / Q000235:genetics; D019175:DNA Methylation / Q000187:drug effects; D044127:Epigenesis, Genetic; D006657:Histones / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D008297:Male; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy
D014408:Biomarkers, Tumor; D006657:Histones